New Delhi: A team of US researchers has turned a deadly fungus into a potent cancer-fighting compound, according to a new study released Monday.
After isolating a new class of molecules from Aspergillus flavus, a toxic crop fungus linked to deaths in the excavations of ancient tombs, the researchers modified the chemicals and tested them against leukaemia cells.
The result was a promising cancer-killing compound that rivals FDA-approved drugs and opens up new frontiers in the discovery of more fungal medicines, according to the study by University of Pennsylvania’s School of Engineering and Applied Science.
“Fungi gave us penicillin. These results show that many more medicines derived from natural products remain to be found,” said Sherry Gao, Presidential Penn Compact Associate Professor in Chemical and Biomolecular Engineering (CBE) and senior author of a new paper in the Nature Chemical Biology journal.
The therapy in question is a class of ribosomally synthesised and post-translationally modified peptides, or RiPPs, pronounced like the “rip” in a piece of fabric.
The name refers to how the compound is produced by the ribosome, a tiny cellular structure that makes proteins, and the fact that it is modified later, in this case, to enhance its cancer-killing properties.
“Purifying these chemicals is difficult,” says Qiuyue Nie, a postdoctoral fellow in CBE and the paper’s first author.
While thousands of RiPPs have been identified in bacteria, only a handful have been found in fungi. In part, this is because past researchers misidentified fungal RiPPs as non-ribosomal peptides and had little understanding of how fungi created the molecules.
“The synthesis of these compounds is complicated,” adds Nie. “But that’s also what gives them this remarkable bioactivity.”
To find more fungal RiPPs, the researchers first scanned a dozen strains of Aspergillus, which previous research suggested might contain more of the chemicals.
By comparing chemicals produced by these strains with known RiPP building blocks, the researchers identified A. flavus as a promising candidate for further study.
Genetic analysis pointed to a particular protein in A. flavus as a source of fungal RiPPs. When the researchers turned the genes that create that protein off, the chemical markers indicating the presence of RiPPs also disappeared.
This novel approach, combining metabolic and genetic information, not only pinpointed the source of fungal RiPPs in A. flavus but could be used to find more fungal RiPPs in the future.
Notably, the compounds had little to no effect on breast, liver or lung cancer cells, or a range of bacteria and fungi, suggesting that asperigimycins’ disruptive effects are specific to certain types of cells, a critical feature for any future medication.
The next step is to test asperigimycins in animal models, with the hope of one day moving to human clinical trials.
IANS
